Literature DB >> 3530705

Diabetic neuropathies. Current concepts in prevention and treatment.

J D Ward.   

Abstract

Diabetic nerve damage leads to a wide variety of unpleasant problems: painful sensations, muscle weakness, numb feet predisposing to ulcers, impotence, and a series of distressing effects due to autonomic dysfunction. At present, there is no single effective treatment for the many clinical syndromes--each of which may well have a different cause. Improved blood glucose control must remain the first line of treatment, hopefully to improve nerve structure and function but also to raise the pain threshold. A variety of sedatives and analgesics may also help some patients. Inhibition of the enzyme aldose reductase with resultant interference with neural sorbitol and myo-inositol metabolism would seem to have a good theoretical basis in therapy, and detailed results of long term clinical trials of aldose reductase inhibitors such as sorbinil and tolrestat are awaited with interest. Their role in the future could be more important in prevention of nerve damage than in attempting to reverse gross end-stage nerve destruction. In diabetic subjects with loss of pain sensation in the foot due to neuropathy or in the more advanced state of foot ulceration, intensive educational and clinical efforts should be exerted to prevent this distressing and common problem. In the future, a more detailed understanding of the biochemical abnormalities occurring in nerves and their effect on nerve function, structure and vasculature may lead to more satisfactory and logical treatments for this the commonest single complication of diabetes.

Entities:  

Mesh:

Year:  1986        PMID: 3530705     DOI: 10.2165/00003495-198632030-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  55 in total

1.  Diabetic neuropathy. Vibration sense and abnormal tendon reflexes in diabetics.

Authors:  I STEINESS
Journal:  Acta Med Scand Suppl       Date:  1963

2.  Diabetic diarrhoea.

Authors:  J M MALINS; J M FRENCH
Journal:  Q J Med       Date:  1957-10

3.  Axonal transport of cholinergic transmitter enzymes in vagus and sciatic nerves of rats with acute experimental diabetes mellitus; correlation with motor nerve conduction velocity and effects of insulin.

Authors:  J H Mayer; D R Tomlinson
Journal:  Neuroscience       Date:  1983-08       Impact factor: 3.590

4.  Cardiorespiratory arrest and diabetic autonomic neuropathy.

Authors:  M M Page; P J Watkins
Journal:  Lancet       Date:  1978-01-07       Impact factor: 79.321

5.  Venous oxygenation in the diabetic neuropathic foot: evidence of arteriovenous shunting?

Authors:  A J Boulton; J H Scarpello; J D Ward
Journal:  Diabetologia       Date:  1982-01       Impact factor: 10.122

6.  Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy.

Authors:  D Finegold; S A Lattimer; S Nolle; M Bernstein; D A Greene
Journal:  Diabetes       Date:  1983-11       Impact factor: 9.461

7.  The natural history of painful diabetic neuropathy--a 4-year study.

Authors:  A J Boulton; W D Armstrong; J H Scarpello; J D Ward
Journal:  Postgrad Med J       Date:  1983-09       Impact factor: 2.401

8.  Axonal atrophy in sensory nerves of the diabetic BB-Wistar rat: a possible early correlate of human diabetic neuropathy.

Authors:  A A Sima; M Bouchier; H Christensen
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

9.  A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy.

Authors:  R J Young; D J Ewing; B F Clarke
Journal:  Diabetes       Date:  1983-10       Impact factor: 9.461

10.  Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry.

Authors:  P J Dyck; W R Sherman; L M Hallcher; F J Service; P C O'Brien; L A Grina; P J Palumbo; C J Swanson
Journal:  Ann Neurol       Date:  1980-12       Impact factor: 10.422

View more
  4 in total

Review 1.  Aldose reductase inhibitors and late complications of diabetes.

Authors:  P Benfield
Journal:  Drugs       Date:  1986       Impact factor: 9.546

2.  Use of ion channel blockers in the exploration of possible mechanisms involved in the myopathy of diabetic mice.

Authors:  S Y Lin-Shiau; S H Liu; M J Lin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-09       Impact factor: 3.000

Review 3.  The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

Authors:  J M van Gerven; A M Tjon-A-Tsien
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

4.  Clinical experience with cyclandelate in insulin-dependent diabetic patients with neuropathy.

Authors:  I H De Leeuw; P Van Rooy; M Moeremans; M Driessens
Journal:  Drugs       Date:  1987       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.